anonymous
Guest
anonymous
Guest
While you are wallowing in negativity, look at past performance: Lipitor was third to market. If....big if...Ertugliflozin comes to market with strong data, it could dominate. Why would Merck sleep with the devil, Pfizer?
If you aren't used to re-org's every two years, you might want to go into another sales field. It's the norm for pharma.